Having trouble accessing articles? Reset your cache.

Carolus: Targeting cytokines

Carolus developing anti-inflammatory peptides with better safety profile

While cytokines are known to be effective targets to treat autoimmune and inflammatory diseases, inhibiting these molecules can restrict the defensive functions of the immune system and increase a patient's susceptibility to infection. Carolus Therapeutics Inc. believes its peptides can reduce inflammation while avoiding immunosuppression by specifically disrupting the interactions of pro-inflammatory cytokines.

President and CEO Court Turner told BioCentury that the problem with most potent anti-inflammatory agents that target cytokines is that "they are so competitive that they block all cognate ligands, and you start running into side effects."

To avoid these

Read the full 919 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers